Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Oxytocin Treatment for Social Deficits in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medically healthy outpatients between 6 and 12 years of age (cut off 12 years and 11 months)~* Intelligence Quotient \> 40~* Diagnosis of autism spectrum disorder based on the Autism Diagnostic Interview - Revised, Autism Diagnostic Observation Schedule, and DSM-IV criteria~* Clinical Global Impression severity rating of 4 or higher~* Care provider who can reliably bring subject to clinic visits, provide trustworthy ratings, and interacts with the subject on a regular basis~* Stable medications for at least 4 weeks~* No planned changes in psychosocial interventions during the trial~* Willingness to provide blood samples.~Exclusion Criteria:~* Diagnostics and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder~* Regular nasal obstruction or nosebleeds~* Active medical problems: unstable seizures, significant physical illness (e.g., serious liver, renal, or cardiac pathology)~* Sensitivity to preservatives (in particular E 216, E 218, and chlorobutanol hemihydrate)~* A genetic abnormality (e.g., Fragile X Syndrome)~* Significant hearing or vision impairments~* Habitually drinks large volumes of water~* Pregnancy, breastfeeding, or child birth within the last 6 months~* Sexually active females not using a reliable method of contraception.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Oxytocin nasal spray (Type: ACTIVE_COMPARATOR): Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
- Placebo nasal spray (Type: PLACEBO_COMPARATOR): The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).